UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Challenges of Antibacterial Discovery

Clinical Microbiology Reviews, 2011-01, Vol.24 (1), p.71-109

SILVER, Lynn L

2011

Volltextzugriff (PDF)

What is an “ideal” antibiotic? Discovery challenges and path forward

Biochemical pharmacology, 2017-06, Vol.133, p.63-73

2017

Volltextzugriff (PDF)

Viable screening targets related to the bacterial cell wall

Annals of the New York Academy of Sciences, 2013-01, Vol.1277 (1), p.29-53

Silver, Lynn L.

2013

Volltextzugriff (PDF)

Fosfomycin: Mechanism and Resistance

Cold Spring Harbor perspectives in medicine, 2017-02, Vol.7 (2), p.a025262

Silver, Lynn L

2017

Volltextzugriff (PDF)

A Gestalt approach to Gram-negative entry

Bioorganic & medicinal chemistry, 2016-12, Vol.24 (24), p.6379-6389

Silver, Lynn L.

2016

Volltextzugriff (PDF)

Appropriate Targets for Antibacterial Drugs

Cold Spring Harbor perspectives in biology, 2016-12, Vol.6 (12), p.a030239

Silver, Lynn L

2016

Volltextzugriff (PDF)

Multi-targeting by monotherapeutic antibacterials

Nature reviews. Drug discovery, 2007-01, Vol.6 (1), p.41-55

Silver, Lynn L

2007

Volltextzugriff (PDF)

Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center

Antimicrobial Agents and Chemotherapy, 2004-12, Vol.48 (12), p.4793-4799

2004

Volltextzugriff (PDF)

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

Antimicrobial agents and chemotherapy, 2022-03, Vol.66 (3), p.e0199121

2022

Volltextzugriff (PDF)

Discovery of FabH/FabF Inhibitors from Natural Products

Antimicrobial Agents and Chemotherapy, 2006-02, Vol.50 (2), p.519-526

2006

Volltextzugriff (PDF)

Analysis of the clinical antibacterial and antituberculosis pipeline

The Lancet infectious diseases, 2019-02, Vol.19 (2), p.e40-e50

2019

Volltextzugriff (PDF)

Natural products as a source of drug leads to overcome drug resistance

Future microbiology, 2015-11, Vol.10 (11), p.1711-1718

Silver, Lynn L

2015

Volltextzugriff (PDF)

Small Molecular Weapons against Multi-Drug Resistance

Accounts of chemical research, 2021-07, Vol.54 (13), p.2785-2787

2021

Volltextzugriff (PDF)

Antibacterials for any target

Nature biotechnology, 2014-11, Vol.32 (11), p.1102-1104

Silver, Lynn L

2014

Volltextzugriff (PDF)

Determination of Selectivity and Efficacy of Fatty Acid Synthesis Inhibitors

The Journal of biological chemistry, 2005-01, Vol.280 (2), p.1669-1677

2005

Volltextzugriff (PDF)

Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1

Antimicrobial agents and chemotherapy, 2016-02, Vol.60 (2), p.936-945

2016

Volltextzugriff (PDF)

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps

Antimicrobial agents and chemotherapy, 2024-08, Vol.68 (8)

2024

Volltextzugriff (PDF)

Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?

Biochemical pharmacology, 2006-03, Vol.71 (7), p.996-1005

Silver, Lynn L.

2006

Volltextzugriff (PDF)

Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!"

Antimicrobial agents and chemotherapy, 2022-04, Vol.66 (4), p.e0022322-e0022322

2022

Volltextzugriff (PDF)

70th Anniversary Collection for the Microbiology Society: Journal of Medical Microbiology

Journal of medical microbiology, 2015-12, Vol.64 (12), p.1457-1461

2015

Volltextzugriff (PDF)

Multitarget ligands in antibacterial research: progress and opportunities

Expert opinion on drug discovery, 2013-02, Vol.8 (2), p.143-156

2013

Volltextzugriff (PDF)

Are natural products still the best source for antibacterial discovery? The bacterial entry factor

Expert opinion on drug discovery, 2008-05, Vol.3 (5), p.487-500

Silver, Lynn L

2008

Volltextzugriff (PDF)

Novel inhibitors of bacterial cell wall synthesis

Current opinion in microbiology, 2003-10, Vol.6 (5), p.431-438

Silver, Lynn L

2003

Volltextzugriff (PDF)

A persistent problem

Journal of medical microbiology, 2011-03, Vol.60 (Pt 3), p.267-268

Silver, Lynn L

2011

Volltextzugriff (PDF)

In Vitro Activities of the Potent, Broad-Spectrum Carbapenem MK-0826 (L-749,345) against Broad-Spectrum β-Lactamase-and Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli Clinical Isolates

Antimicrobial Agents and Chemotherapy, 1999-05, Vol.43 (5), p.1170-1176

1999

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(97)
Life Sciences & Biomedicine
(86)
Humans
(65)
Biological And Medical Sciences
(34)
Female
(32)
Medical Sciences
(30)
Male
(25)
Anti-Bacterial Agents - Pharmacology
(23)
Pharmacology & Pharmacy
(22)
Microbial Sensitivity Tests
(18)
Pharmacology. Drug Treatments
(18)
Adult
(17)
Animals
(16)
Microbiology
(16)
Middle Aged
(16)
Antibacterial Agents
(14)
Anti-Bacterial Agents - Chemistry
(13)
Antibiotics
(12)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(12)
Aged
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Challenges of Antibacterial Discovery

What is an “ideal” antibiotic? Discovery challenges and path forward

Viable screening targets related to the bacterial cell wall

Fosfomycin: Mechanism and Resistance

A Gestalt approach to Gram-negative entry

Appropriate Targets for Antibacterial Drugs

Multi-targeting by monotherapeutic antibacterials

Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

Discovery of FabH/FabF Inhibitors from Natural Products

Analysis of the clinical antibacterial and antituberculosis pipeline

Natural products as a source of drug leads to overcome drug resistance

Small Molecular Weapons against Multi-Drug Resistance

Antibacterials for any target

Determination of Selectivity and Efficacy of Fatty Acid Synthesis Inhibitors

Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps

Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?

Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!"

70th Anniversary Collection for the Microbiology Society: Journal of Medical Microbiology

Multitarget ligands in antibacterial research: progress and opportunities

Are natural products still the best source for antibacterial discovery? The bacterial entry factor

Novel inhibitors of bacterial cell wall synthesis

A persistent problem

In Vitro Activities of the Potent, Broad-Spectrum Carbapenem MK-0826 (L-749,345) against Broad-Spectrum β-Lactamase-and Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli Clinical Isolates

Suchergebnisse filtern